BMS expands Tempus data pact for AI oncology discovery
What's the deal? Chicago-based Tempus and Bristol-Myers Squibb (BMS) have expanded their multi-year collaboration, announced 25 October 2026. Under the extended agreement, BMS will license Tempus's multimodal oncology data through 2031 — real-world, de-identified patient data combining clinical records, genomics, pathology imaging and other signals — making BMS one of Tempus's largest data licensors.
Why it matters: BMS will also get access to Tempus's Lens platform, an AI-first system that lets researchers train and run advanced AI models on de-identified patient data using dedicated GPU computing. The aim is to surface new biological insights, find novel drug targets and improve the odds of success when developing oncology therapies at scale.
Context: The deal builds on an existing Tempus-BMS relationship that already applies AI and real-world data to optimise clinical trial design in oncology and neuroscience programs. Tempus CEO Eric Lefkofsky said the combination of a vast multimodal data asset with dedicated GPU power inside Lens is intended to speed up drug discovery and support the shift toward precision oncology. Financial terms of the expanded licence were not disclosed.
Read more: BioSpace, 26 Oct 2026
